Published in
Springer (part of Springer Nature), Cancer Chemotherapy and Pharmacology, 2(75), p. 319-324
DOI: 10.1007/s00280-014-2641-3
Links
Tools
Phase II trial of miniDOX (reduced dose docetaxel–oxaliplatin–capecitabine) in “suboptimal” patients with advanced gastric cancer (AGC). TTD 08-02
Journal article published in 2014 by
F. Rivera,
B. Massutí 
,
M. Salcedo,
J. Sastre,
J. Martínez Galán,
M. Valladares-Ayerbes,
R. Serrano,
M.-ª. L. García de Paredes,
J. L. Manzano,
M. Galán,
M. Alsina,
A. L. Yuste Izquierdo,
C. López,
E. Díaz-Rubio,
V. Conde
and other authors.
,
M. Salcedo,
J. Sastre,
J. Martínez Galán,
M. Valladares-Ayerbes,
R. Serrano,
M.-ª. L. García de Paredes,
J. L. Manzano,
M. Galán,
M. Alsina,
A. L. Yuste Izquierdo,
C. López,
E. Díaz-Rubio,
V. Conde
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 